AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUTEP LTD

0.047

+0.0024.44%

Volume:8.70M

Turnover:404.40K

Market Cap:69.26M

PE:-0.87

High:0.048

Open:0.045

Low:0.044

Close:0.045

52wk High:0.470

52wk Low:0.028

Shares:1.47B

Float Shares:1.23B

Volume Ratio:0.41

T/O Rate:0.71%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.054

EPS(LYR):-0.054

ROE:-77.31%

ROA:-42.45%

PB:1.13

PE(LYR):-0.87

Loading ...

Overview Company News Filings

Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says

MT Newswires Live

Immutep Gets a New Bull at Jefferies

Immutep - to Focus Efti Development on Hnscc with CPS < 1 and Neoadjuvant Sts

THOMSON REUTERS

Immutep - Contracts New Manufacturing Run of Efti at 200 L Scale

THOMSON REUTERS

Immutep - Targets Next Efti Clinical Trials Start in 2H Cy2027

THOMSON REUTERS

Immutep Targets 2H 2027 Start for Efti Trials in PD-L1-Negative Head and Neck Cancer, Soft Tissue Sarcoma

Immutep Says Root Cause Analysis Points to Structural Differences in Drug Candidate Used in Discontinued Trial

MT Newswires Live

Immutep Ltd-Immutep Outlines Focused Development Strategy for Efti

THOMSON REUTERS

Australia's Immutep Falls to Near 3-Week Low as 2026 Loss Widens

Immutep Says no Dividends Paid or Declared During Current FY

Immutep - FY Loss Attributable A$79.3 Mln

THOMSON REUTERS

Immutep Says Eftisarc-neo Phase II Eposter on Efti Hrqol in Soft Tissue Sarcoma Accepted for ESMO 2026

Immutep Receives New US Patent for Cancer Treatment Method; Shares Down 4%

MT Newswires Live

Immutep Provides Clinical Update in 1st Line Nsclc: Positive Mature Overall Survival Data from Insight-003 and Update from Tacti-004

THOMSON REUTERS

Immutep - Insight-3 Shows Mature Median Overall Survival of 30.9 Months in 1L Non-squamous Nsclc

THOMSON REUTERS

Immutep - Tacti-4 Root Cause Analysis Ongoing, Results Expected Q3 Cy2026

THOMSON REUTERS

Immutep - no New Safety Signals Observed to Date in Tacti-4

THOMSON REUTERS

Immutep Says Median Overall Survival 30.9 Months for Non-Small Cell Lung Cancer Patients in Phase One Trial

MT Newswires Live

ASX Penny Stocks: Immutep And Two More Companies To Watch

Simply Wall St.

Here's Why We're Watching Immutep's (ASX:IMM) Cash Burn Situation

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/IMM.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.047,"timestamp":1789539120000,"preClose":0.045,"halted":0,"volume":8697659,"delay":0,"changeRate":0.04444444444444449,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.0539,"marketStatus":"Closed","change":0.002,"latestTime":"09-16 16:12:00 AEST","open":0.045,"high":0.048,"low":0.044,"amount":404401,"amplitude":0.088889,"askPrice":0.047,"askSize":7192,"bidPrice":0.046,"bidSize":113636,"shortable":3,"etf":0,"ttmEps":-0.0539,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.045,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.409386,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMM.AU","preClose":0.045,"auctionPrice":0.047,"auctionVolume":727381,"auctionTime":1789539016497,"referencePrice":0.047,"referenceTime":1789554603098,"auction":3,"marketStatus":"盘后竞价","timestamp":1789539016497}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-42.45%","roe":"-77.31%","lyrEps":-0.0539,"volumeRatio":0.409386,"shares":1473721306,"dividePrice":0,"high":0.048,"amplitude":0.088889,"preClose":0.045,"low":0.044,"week52Low":0.028,"pbRate":"1.13","psRate":"3.47","week52High":0.47,"institutionHeld":0,"latestPrice":0.047,"committee":0.880955,"eps":-0.0539,"divideRate":0,"volume":8697659,"delay":0,"ttmEps":-0.0539,"open":0.045,"prevYearClose":0.415,"prevWeekClose":0.056,"prevMonthClose":0.048,"prevQuarterClose":0.053,"fiveDayClose":0.046,"twentyDayClose":0.051,"sixtyDayClose":0.052,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667616451","title":"Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2667616451","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667616451?lang=en_us&edition=fundamental","pubTime":"2026-09-15 13:33","pubTimestamp":1789450429,"startTime":"0","endTime":"0","summary":"Immutep's  eftilagimod alfa drug candidate, or efti, now has a clearer potential development path after the early termination of the TACTI-004 study, according to a Tuesday note by Jefferies.Its root cause analysis increasingly supports TACTI-004 as a potentially isolated product-specific structural issue rather than a failure of efti's biology. The identification of subtle N-glycan differences in the efti material used in TACTI-004 is potentially important.With prior efti data intact, head and neck squamous cell carcinoma prioritization, fast-track status, and planned manufacturing work, the risk and reward look more constructive despite residual execution risk.The brokerage upgraded its rating on Immutep to buy from hold with the price target rising to AU$0.08 per share from AU$0.04.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667692474","title":"Immutep Gets a New Bull at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2667692474","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667692474?lang=en_us&edition=fundamental","pubTime":"2026-09-15 09:09","pubTimestamp":1789434540,"startTime":"0","endTime":"0","summary":"0109 GMT - Immutep gets a new bull at Jefferies, where analyst David Stanton sees a clearer potential development path for the biotechnology company's lead product candidate. Raising his recommendation to buy from hold, Stanton is encouraged by the Australian company's update that the early discontinuation of a lung cancer study doesn't appear to be linked to clinical factors or trial execution. Emerging evidence supports a cautiously constructive view that the outcome stemmed from an isolated manufacturing or product-characterisation issue, Stanton explains in a note to clients. Risk/reward looks more constructive to Stanton, who now includes Immutep's phase IIhead and neck squamous cell carcinoma opportunity in his valuation. Jefferies doubles its target price to 8 Australian cents. Shares are flat at 4.7 Australian cents.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMP","IMM.AU","BK7067","BK4139","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666521234","title":"Immutep - to Focus Efti Development on Hnscc with CPS < 1 and Neoadjuvant Sts","url":"https://stock-news.laohu8.com/highlight/detail?id=2666521234","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666521234?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:00","pubTimestamp":1789128036,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666212615","title":"Immutep - Contracts New Manufacturing Run of Efti at 200 L Scale","url":"https://stock-news.laohu8.com/highlight/detail?id=2666212615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666212615?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:00","pubTimestamp":1789128036,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530F5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666212325","title":"Immutep - Targets Next Efti Clinical Trials Start in 2H Cy2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666212325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666212325?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:00","pubTimestamp":1789128036,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530F5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666151081","title":"Immutep Targets 2H 2027 Start for Efti Trials in PD-L1-Negative Head and Neck Cancer, Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2666151081","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666151081?lang=en_us&edition=fundamental","pubTime":"2026-09-11 10:32","pubTimestamp":1789093949,"startTime":"0","endTime":"0","summary":"Immutep targets 2H 2027 start for efti trials in PD-L1-negative head and neck cancer, soft tissue sarcomaImmutep reset efti’s registration strategy, prioritizing head and neck cancer in PDL1negative p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL8SLnt4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666512317","title":"Immutep Says Root Cause Analysis Points to Structural Differences in Drug Candidate Used in Discontinued Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666512317","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666512317?lang=en_us&edition=fundamental","pubTime":"2026-09-11 09:02","pubTimestamp":1789088547,"startTime":"0","endTime":"0","summary":"Immutep  conducted a root cause analysis covering clinical, pharmacological, and manufacturing aspects for its eftilagimod alfa drug candidate, or efti, which identified structural differences between the efti used in the discontinued TACTI-004 trial and the efti used in earlier successful clinical studies, according to a Friday Australian bourse filing.The differences, including a difference in N-glycan structure, are considered potentially relevant given the different immune activation profile observed in the TACTI-004 trial. Immutep believes that \"the unexpected outcome of TACTI-004\" cannot be explained by clinical factors or trial execution factors.Due to the analytical differences between efti manufactured at 200 L scale and efti manufactured at 2,000 L scale, a new manufacturing run of efti at 200 L scale was contracted.Future registration-directed clinical development of efti is intended to focus on head and neck squamous cell carcinoma in patients with negative PD-L1 expression","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK4505","BK7508","BK4551","ROOT","BK4107","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666519409","title":"Immutep Ltd-Immutep Outlines Focused Development Strategy for Efti","url":"https://stock-news.laohu8.com/highlight/detail?id=2666519409","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666519409?lang=en_us&edition=fundamental","pubTime":"2026-09-11 07:01","pubTimestamp":1789081308,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUE9KKQV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663021517","title":"Australia's Immutep Falls to Near 3-Week Low as 2026 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2663021517","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663021517?lang=en_us&edition=fundamental","pubTime":"2026-08-31 11:40","pubTimestamp":1788147609,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immutep falls to near 3-week low as 2026 loss widens** Shares of ImmutepIMM.AXfell as much as 4% to A$0.048, marking their lowest level since August 12** Biotechnology firm'sannual losswidens by 29.1% to A$79.3 million  from A$61.4 million in 2025** Including day's moves, stock down 88.2% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL4N44S09S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663025976","title":"Immutep Says no Dividends Paid or Declared During Current FY","url":"https://stock-news.laohu8.com/highlight/detail?id=2663025976","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663025976?lang=en_us&edition=fundamental","pubTime":"2026-08-31 09:32","pubTimestamp":1788139963,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Says No Dividends Paid Or Declared During Current FYAug 31 (Reuters)-Immutep LtdIMM.AX:IMMUTEP LTD -  NO DIVIDENDS PAID OR DECLARED DURING CURRENT FYFurther company coverage:IMM.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44P20Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663040149","title":"Immutep - FY Loss Attributable A$79.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2663040149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663040149?lang=en_us&edition=fundamental","pubTime":"2026-08-31 07:14","pubTimestamp":1788131660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260830:nPLXZ3JZPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653084916","title":"Immutep Says Eftisarc-neo Phase II Eposter on Efti Hrqol in Soft Tissue Sarcoma Accepted for ESMO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653084916","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653084916?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:05","pubTimestamp":1784894709,"startTime":"0","endTime":"0","summary":"Immutep says EFTISARC-NEO Phase II ePoster on efti HRQoL in soft tissue sarcoma accepted for ESMO 2026Immutep flagged an accepted ESMO Congress 2026 ePoster from the Phase II EFTISARC-NEO trial of eft","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL3Nl1BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651126444","title":"Immutep Receives New US Patent for Cancer Treatment Method; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651126444","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651126444?lang=en_us&edition=fundamental","pubTime":"2026-07-14 11:25","pubTimestamp":1783999558,"startTime":"0","endTime":"0","summary":"Immutep  obtained a fourth patent from the US Patent and Trademark Office related to its cancer treatments, according to a Tuesday filing with the Australian bourse.The new patent, which covers methods to treat cancer by administering eftilagimod alfa in combination with PD-1 pathway inhibitors, has an expiry date of Jan. 20, 2036, per the filing.The company is evaluating eftilagimod alfa in a variety of solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, soft tissue sarcoma, and breast cancer.Immutep shares fell nearly 4% in recent Tuesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651811966","title":"Immutep Provides Clinical Update in 1st Line Nsclc: Positive Mature Overall Survival Data from Insight-003 and Update from Tacti-004","url":"https://stock-news.laohu8.com/highlight/detail?id=2651811966","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651811966?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA2HW17Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651196131","title":"Immutep - Insight-3 Shows Mature Median Overall Survival of 30.9 Months in 1L Non-squamous Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2651196131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651196131?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA2HW17Z:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651119690","title":"Immutep - Tacti-4 Root Cause Analysis Ongoing, Results Expected Q3 Cy2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119690","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651119690?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA2HW17Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651119615","title":"Immutep - no New Safety Signals Observed to Date in Tacti-4","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651119615?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944003,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA2HW17Z:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651819633","title":"Immutep Says Median Overall Survival 30.9 Months for Non-Small Cell Lung Cancer Patients in Phase One Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651819633","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651819633?lang=en_us&edition=fundamental","pubTime":"2026-07-13 14:36","pubTimestamp":1783924582,"startTime":"0","endTime":"0","summary":"Immutep  said the median overall patient survival was 30.9 months in patients in its INSIGHT-003 phase one trial, evaluating eftilagimod alfa, or efti, in combination with Merck's anti-PD-1 therapy Keytruda, or pembrolizumab, and chemotherapy as first-line therapy for advanced or metastatic non-small cell lung cancer in 51 evaluable non-squamous patients, according to a Monday Australian bourse filing.Around 92% of patients enrolled in the trial had no or low programmed death-ligand 1  expression, with a tumor proportion score under 50%. The median overall survival was 37.8 months in patients with a tumor proportion score of over 50%.The results compare favorably with historical benchmarks, the filing said.Preliminary immune monitoring data generated from its discontinued TACTI-004 phase three trial indicated that patients treated with efti showed a different immune activation profile compared with those observed in previous studies. The TACTI-004 analysis is ongoing, with additional r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645856336","title":"ASX Penny Stocks: Immutep And Two More Companies To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2645856336","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645856336?lang=en_us&edition=fundamental","pubTime":"2026-06-24 03:02","pubTimestamp":1782241379,"startTime":"0","endTime":"0","summary":"The Australian market is poised for a 20-point advance at open, reflecting global optimism despite recent tech sector jitters overseas. While the term 'penny stocks' might seem outdated, these smaller or newer companies still hold significant potential when supported by strong financials. In this article, we explore three promising penny stocks that combine balance sheet strength with growth opportunities, offering investors a chance to uncover hidden value in quality companies.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-oec/orbital-shares/news/asx-penny-stocks-immutep-and-two-more-companies-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-oec/orbital-shares/news/asx-penny-stocks-immutep-and-two-more-companies-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7104","OEC.AU","BK7508","TCG.AU","IMM.AU","BK7115","BK7506","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644061818","title":"Here's Why We're Watching Immutep's (ASX:IMM) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2644061818","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644061818?lang=en_us&edition=fundamental","pubTime":"2026-06-20 04:03","pubTimestamp":1781899385,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/heres-why-were-watching-immuteps-asximm-cash-burn-situation","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/heres-why-were-watching-immuteps-asximm-cash-burn-situation","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":59,"code":"91000000","status":"200"}]}}